# ImageneBio, Inc.: overview

IMA · Nasdaq · CIK 1835579 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ima.md) · [Financials](/companies/ima/financials.md) · [Filings](/companies/ima/filings.md) · [Insiders](/companies/ima/insiders.md)

Latest reported revenue: [$0](/filings/0001193125-26-099434.md) for Q4 FY2025, three months to 2025-12-31, from the 10-K filed Mar 10, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-099434).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [3,500](/filings/0001193125-25-275932.md) | [0.0 d](/filings/0001193125-26-099434.md) | [800](/filings/0001193125-26-212073.md) | [0.0 d](/filings/0001193125-26-333920.md) | [0.0](/filings/0001193125-25-275932.md) | [0.0 d](/filings/0001193125-26-099434.md) | not reported | not reported |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(58.2%)](/filings/0001193125-25-275932.md) | not reported | [(749.4%)](/filings/0001193125-26-212073.md) | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | [(90.9%)](/filings/0001193125-25-275932.md) | not reported | [(759.6%)](/filings/0001193125-26-333920.md) | not reported | not reported | not reported | not reported | not reported |
| Diluted EPS | $ per share | [(2.58)](/filings/0001193125-25-275932.md) | not reported | [(3.80)](/filings/0001193125-26-212073.md) | [(4.46)](/filings/0001193125-26-333920.md) | [(2.91)](/filings/0001193125-25-275932.md) | not reported | [(0.95)](/filings/0001193125-26-212073.md) | [(0.63)](/filings/0001193125-26-333920.md) |
| Free cash flow | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [31.0](/filings/0000950170-23-007681.md) | [15.6](/filings/0000950170-24-029651.md) | [9.2](/filings/0000950170-25-034188.md) | [3.5](/filings/0001193125-26-099434.md) | [0.8](/filings/0001193125-26-099434.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(110.2%)](/filings/0000950170-23-007681.md) | [(454.0%)](/filings/0000950170-24-029651.md) | [(823.3%)](/filings/0000950170-25-034188.md) | [(1057.1%)](/filings/0001193125-26-099434.md) | [(6056.4%)](/filings/0001193125-26-099434.md) |
| Net margin | % | [(110.1%)](/filings/0000950170-23-007681.md) | [(440.3%)](/filings/0000950170-24-029651.md) | [(744.2%)](/filings/0000950170-25-034188.md) | [(1044.8%)](/filings/0001193125-26-099434.md) | [(5668.6%)](/filings/0001193125-26-099434.md) |
| Diluted EPS | $ per share | [(1.22)](/filings/0000950170-23-007681.md) | [(1.90)](/filings/0000950170-24-029651.md) | [(1.63)](/filings/0000950170-25-034188.md) | [(22.10)](/filings/0001193125-26-099434.md) | [(9.64)](/filings/0001193125-26-099434.md) |
| Free cash flow | $m | [(62.0)](/filings/0000950170-23-007681.md) | [(75.5)](/filings/0000950170-24-029651.md) | [(80.2)](/filings/0000950170-25-034188.md) | not reported | not reported |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/ima/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BVF INC/IL](/funds/1056807.md) | 2026-06-30 | $6.5m | 1,110,002 |  | Unchanged |
| [Blue Owl Capital Holdings LP](/funds/1858703.md) | 2026-06-30 | $5.4m | 917,692 |  | Reduced −41,645 |
| [ORBIMED ADVISORS LLC](/funds/1055951.md) | 2026-06-30 | $5.4m | 909,269 |  | Added +530,713 |
| [Cable Car Capital, LP](/funds/1699575.md) | 2026-06-30 | $4.6m | 781,599 |  | Added +26,850 |
| [Omega Fund Management, LLC](/funds/1637359.md) | 2026-06-30 | $2.7m | 455,361 |  | Unchanged |
| [RTW INVESTMENTS, LP](/funds/1493215.md) | 2026-06-30 | $2.0m | 334,445 |  | Unchanged |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $1.9m | 320,518 |  | Reduced −4,637 |
| [Trails Edge Capital Partners, LP](/funds/2077247.md) | 2026-06-30 | $1.7m | 282,004 |  | New +282,004 |
| [BML Capital Management, LLC](/funds/1616824.md) | 2026-06-30 | $1.2m | 200,730 |  | Unchanged |
| [Monashee Investment Management LLC](/funds/1627608.md) | 2026-06-30 | $1.1m | 192,344 |  | New +192,344 |

## Recent filings

[All 332 filings](/companies/ima/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-05 | 08:10 ET | [10-Q](/filings/0001193125-26-333920.md) | Quarterly report, period 2026-06-30 | 0001193125-26-333920 |
| 2026-08-05 | 08:05 ET | [8-K](/filings/0001193125-26-333912.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-333912 |
| 2026-07-23 | 16:25 ET | [8-K](/filings/0001193125-26-314167.md) | 5.02 Departure or appointment of officers or directors; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-314167 |
| 2026-06-26 | 16:01 ET | [8-K](/filings/0001193125-26-285424.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-285424 |
| 2026-06-17 | 16:05 ET | [8-K](/filings/0001193125-26-274139.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-274139 |
| 2026-05-07 | 16:24 ET | [10-Q](/filings/0001193125-26-212073.md) | Quarterly report, period 2026-03-31 | 0001193125-26-212073 |
| 2026-05-07 | 16:12 ET | [8-K](/filings/0001193125-26-211935.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-211935 |
| 2026-04-30 | 16:31 ET | [DEF 14A](/filings/0001140361-26-018267.md) | Proxy statement, period 2026-06-16 | 0001140361-26-018267 |
| 2026-04-29 | 19:07 ET | [SCHEDULE 13D/A](/filings/0000947871-26-000483.md) | Ownership report, active investor, amended | 0000947871-26-000483 |
| 2026-04-21 | 16:00 ET | [SCHEDULE 13D](/filings/0001193125-26-166691.md) | Ownership report, active investor | 0001193125-26-166691 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-099434.md), filed Mar 10, 2026.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 1835579
- Tickers: IMA
- Exchange: Nasdaq
- SIC code: 2836 Biological Products, (No Diagnostic Substances)
- State of incorporation: DE
- Filer category: Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.